Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

Similar articles for PubMed (Select 25118216)

1.

Development of an anti-claudin-3 and -4 bispecific monoclonal antibody for cancer diagnosis and therapy.

Li X, Iida M, Tada M, Watari A, Kawahigashi Y, Kimura Y, Yamashita T, Ishii-Watabe A, Uno T, Fukasawa M, Kuniyasu H, Yagi K, Kondoh M.

J Pharmacol Exp Ther. 2014 Oct;351(1):206-13. doi: 10.1124/jpet.114.216911. Epub 2014 Aug 12.

PMID:
25118216
2.

A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.

Weiner LM, Holmes M, Adams GP, LaCreta F, Watts P, Garcia de Palazzo I.

Cancer Res. 1993 Jan 1;53(1):94-100.

3.
4.
5.
6.

Granulocyte-colony stimulating factor enhances chimeric antibody Nd2 dependent cytotoxicity against pancreatic cancer mediated by polymorphonuclear neutrophils.

Tamamori Y, Sawada T, Nishihara T, Yamashita Y, Ohira M, Ho JJ, Kim YS, Hirakawa-Y S Chung K.

Int J Oncol. 2002 Sep;21(3):649-54.

PMID:
12168113
7.

Binding and functional properties of a mouse-human chimeric monoclonal antibody of the human IgG1 subclass with specificity for human carcinomas.

Liao SK, Horton L, Flahart RE, O'Rear L, Crumpacker D, Imbaratto JW, Yannelli JR, Robinson RR, Oldham RK.

Hum Antibodies Hybridomas. 1990;1(2):66-76.

PMID:
2103354
8.

Mouse monoclonal antibodies for experimental immunotherapy promotes killing of tumor cells.

Larson LN, Johansson C, Lindholm L, Holmgren J.

Int J Cancer. 1988 Dec 15;42(6):877-82.

PMID:
3192334
9.

Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.

Bruckheimer EM, Fazenbaker CA, Gallagher S, Mulgrew K, Fuhrmann S, Coffman KT, Walsh W, Ready S, Cook K, Damschroder M, Kinch M, Kiener PA, Woods R, Gao C, Dall'Acqua W, Wu H, Coats S.

Neoplasia. 2009 Jun;11(6):509-17, 2 p following 517.

10.

Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity.

Steplewski Z, Sun LK, Shearman CW, Ghrayeb J, Daddona P, Koprowski H.

Proc Natl Acad Sci U S A. 1988 Jul;85(13):4852-6.

11.

Antitumor effects of a bispecific antibody targeting CA19-9 antigen and CD16.

Garcia de Palazzo I, Holmes M, Gercel-Taylor C, Weiner LM.

Cancer Res. 1992 Oct 15;52(20):5713-9.

12.

Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicity.

Li G, Zhang L, Chen E, Wang J, Jiang X, Chen JH, Wickman G, Amundson K, Bergqvist S, Zobel J, Buckman D, Baxi SM, Bender SL, Casperson GF, Hu-Lowe DD.

Cancer Res. 2010 Dec 15;70(24):10243-54. doi: 10.1158/0008-5472.CAN-10-1996. Erratum in: Cancer Res. 2011 Feb 15;71(4):1507.

13.

Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity.

Kaneko MK, Kunita A, Abe S, Tsujimoto Y, Fukayama M, Goto K, Sawa Y, Nishioka Y, Kato Y.

Cancer Sci. 2012 Nov;103(11):1913-9. doi: 10.1111/j.1349-7006.2012.02385.x. Epub 2012 Aug 27.

PMID:
22816430
14.

Comparative binding and preclinical localization and therapy studies with radiolabeled human chimeric and murine 17-1A monoclonal antibodies.

Buchsbaum DJ, Brubaker PG, Hanna DE, Glatfelter AA, Terry VH, Guilbault DM, Steplewski Z.

Cancer Res. 1990 Feb 1;50(3 Suppl):993s-999s.

15.

Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers.

Suzuki M, Kato-Nakano M, Kawamoto S, Furuya A, Abe Y, Misaka H, Kimoto N, Nakamura K, Ohta S, Ando H.

Cancer Sci. 2009 Sep;100(9):1623-30. doi: 10.1111/j.1349-7006.2009.01239.x. Epub 2009 Jun 1.

PMID:
19555390
16.
17.

Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy.

Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG, Jakobovits A.

Cancer Res. 1999 Mar 15;59(6):1236-43.

18.

Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells.

Rozan C, Cornillon A, Pétiard C, Chartier M, Behar G, Boix C, Kerfelec B, Robert B, Pèlegrin A, Chames P, Teillaud JL, Baty D.

Mol Cancer Ther. 2013 Aug;12(8):1481-91. doi: 10.1158/1535-7163.MCT-12-1012. Epub 2013 Jun 11.

19.
20.

Suppression of tumor growth by in vivo administration of a recombinant human-mouse chimeric monoclonal antibody.

Yokoyama M, Nishimura Y, Watanabe T.

Jpn J Cancer Res. 1987 Nov;78(11):1251-7.

PMID:
2961718
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk